早期类风湿关节炎甲氨蝶呤治疗策略:前瞻性队列研究
该多中心前瞻性队列纳入2007-2017年间症状出现1年内、符合ACR/EULAR分类标准的早期RA患者1484例,评估甲氨蝶呤(MTX)及非MTX为基础的治疗策略在真实世界中的起始与调整模式。多数患者起始MTX单药治疗;皮下MTX单药治疗者较口服MTX单药治疗者治疗改变更少且持续治疗时间更长;生物制剂和三联治疗者无治疗改变时间更长。
要点
- 皮下MTX单药较口服MTX单药治疗改变更少且持续治疗时间更长。
- 多数治疗调整涉及加用DMARD或换用非MTX的DMARD。
- 生物制剂或三联治疗者较口服MTX单药无治疗改变时间更长。
核心结论
- 临床实践中基于MTX的治疗处方存在很大变异性。
- 研究结果支持将皮下MTX单药或MTX联合方案作为初始治疗。
- 初始MTX为基础治疗后,起始生物制剂或三联治疗者较口服MTX单药治疗改变时间更长。
研究设计与样本
- 多中心、 incident早期RA队列,2007-2017年入组,症状出现1年内且符合ACR/EULAR分类标准。
- 纳入在队列入组90天内起始MTX(±其他DMARDs)治疗的成人RA患者1484例。
- 比较4种初始MTX为基础治疗至治疗改变的时间,以及首次改变后至第二次治疗改变的时间。
主要发现
- 多数患者起始MTX单药治疗(口服或皮下)。
- 皮下MTX单药治疗者较口服MTX单药治疗者治疗改变比例更低(45% versus 79%),且持续治疗时间更长(HR 0.52 [95% CI 0.4-0.67])。
- 多数治疗调整涉及加用DMARD或换用非MTX的DMARD。
- 使用生物制剂者(HR 0.26 [95% CI 0.16-0.42])和三联治疗者(HR 0.57 [95% CI 0.38-0.85])无治疗改变时间更长。
关键数值与推荐
- 治疗改变定义包括:MTX单药治疗途径改变、加用或停用DMARD或生物制剂、改变DMARD或生物制剂的剂量/频率。
- 皮下MTX单药治疗者治疗改变比例45% versus 口服MTX单药治疗者79%。
- 皮下MTX单药治疗者持续治疗时间HR 0.52(95% CI 0.4-0.67)。
- 生物制剂者无治疗改变时间HR 0.26(95% CI 0.16-0.42)。
- 三联治疗者无治疗改变时间HR 0.57(95% CI 0.38-0.85)。
临床怎么用
- 早期RA初始治疗可考虑皮下MTX单药或MTX联合方案。
- 初始MTX为基础治疗后,可考虑生物制剂或三联治疗以延长无治疗改变时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess real-world practice patterns surrounding treatment initiation and adjustments over time for methotrexate (MTX) and non-MTX-based treatment strategies in early rheumatoid arthritis (RA). METHODS: We studied a multicenter, incident early RA cohort (enrolled 2007-2017 within 1 year of symptoms) who fulfilled American College of Rheumatology/European League Against Rheumatism criteria. Adult patients with RA were eligible if treatment with MTX (± other disease-modifying antirheumatic drugs [DMARDs]) was initiated within 90 days of cohort entry. We compared time until treatment change for 4 initial MTX-based therapies and time to second treatment change after the first change. The definition of treatment change included changing of route for MTX monotherapy, adding or stopping a DMARD or biologic, and changing dose/frequency of a DMARD or biologic. RESULTS: There was great variability of treatment at initiation and during therapy adjustment. In 1,484 patients with early RA, the majority initiated MTX monotherapy (oral or subcutaneous [SC]). Patients receiving SC MTX monotherapy changed treatment less (45% versus 79%) and remained on treatment longer (hazard ratio [HR] 0.52 [95% confidence interval (95% CI) 0.4-0.67]) than those receiving oral MTX monotherapy. Most therapy adjustments involved adding a DMARD or changing to a non-MTX DMARD. Those adults taking biologics and who were receiving triple therapy had a longer time without treatment change (HR 0.26 [95% CI 0.16-0.42] and HR 0.57 [95% CI 0.38-0.85], respectively). CONCLUSION: We found large variability in the way MTX-based therapies are prescribed in clinical practice. Our findings support the use of SC MTX monotherapy or MTX combination as initial therapy. For subsequent treatment after initial MTX-based therapy, those patients initiating either biologics or triple therapy had a longer time to treatment change than oral MTX monotherapy.
引用
- Moura CS, Schieir O, Valois MF, et al. Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort. Arthritis Care Res (Hoboken). 2020. PMID: 31112011. doi:10.1002/acr.23927
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。